Literature DB >> 10594732

Selective incorporation and specific cytocidal effect as the cellular basis for the antimelanoma action of sulphur containing tyrosine analogs.

P D Thomas1, H Kishi, H Cao, M Ota, T Yamashita, S Singh, K Jimbow.   

Abstract

Tyrosine analogs are good candidates for developing melanoma chemotherapy because melanogenesis is inherently toxic and uniquely expressed in melanocytic cells. Sulphur containing substrate (tyrosine) analogs, N-acetyl-4-S-cysteaminylphenol (NAcCAP) and N-propionyl-4-S-cysteaminylphenol (NPrCAP), have been shown to have potent antimelanoma activity in mice bearing melanoma. Both NAcCAP and NPrCAP show selective cytotoxicity towards melanoma cell lines. But the mechanism leading to selectivity is not clear as these drugs are also toxic to other cell lines to a lesser extent. Here we show that these drugs have both cytostatic and cytocidal effects, which could account for this. Cytostatic effect is suggested by DNA flow cytometry. The drug causes cell cycle changes in four human cell lines (normal skin fibroblasts, HeLa cells, and melanoma cell lines, C32 and SK-MEL-23) in a dose-dependent manner blocking cells in S phase with concomitant decrease in the number of cells in G1 phase. There is also a gradual decrease in cells in G2 + M phases. The dose-concentration curves give IC50 values in the range of 50-400 microM and the melanotic melanoma cell line SK-MEL-23 has the lowest IC50 value consistent with our hypothesis that these drugs are selective towards melanoma cells. The concentration-dependent accumulation of cells in S phase suggest a cytostatic effect as a consequence of inhibition of DNA synthesis in agreement with [3H] thymidine incorporation assay. There is a highly specific uptake of [14C]NAcCAP and irreversible damage to DNA synthesis machinery in SK-MEL-23 cells, indicating a melanotic-specific cytocidal effect as well. Trypan blue exclusion study and competitive inhibition assay indicated that visible cytocidal effect occurs slowly and oxidative stress resulting from tyrosinase mediated oxidation of the drug appears to be the underlying mechanism. The primary antimelanoma effect of cysteaminylphenols derives from a selective cytostatic effect, but is followed by a specific cytocidal action rendering the drugs useful for targeted melanoma chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10594732     DOI: 10.1046/j.1523-1747.1999.00781.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

1.  Stress chaperone mortalin regulates human melanogenesis.

Authors:  Renu Wadhwa; Didik Priyandoko; Ran Gao; Nashi Widodo; Nupur Nigam; Ling Li; Hyo Min Ahn; Chae-Ok Yun; Nobuhiro Ando; Christian Mahe; Sunil C Kaul
Journal:  Cell Stress Chaperones       Date:  2016-04-07       Impact factor: 3.667

Review 2.  Targeted therapy for malignant melanoma.

Authors:  C K Brown; J M Kirkwood
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

Review 3.  Immunomodulation of Melanoma by Chemo-Thermo-Immunotherapy Using Conjugates of Melanogenesis Substrate NPrCAP and Magnetite Nanoparticles: A Review.

Authors:  Yasuaki Tamura; Akira Ito; Kazumasa Wakamatsu; Takafumi Kamiya; Toshihiko Torigoe; Hiroyuki Honda; Toshiharu Yamashita; Hisashi Uhara; Shosuke Ito; Kowichi Jimbow
Journal:  Int J Mol Sci       Date:  2022-06-09       Impact factor: 6.208

4.  Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles.

Authors:  Kowichi Jimbow; Yasue Ishii-Osai; Shosuke Ito; Yasuaki Tamura; Akira Ito; Akihiro Yoneta; Takafumi Kamiya; Toshiharu Yamashita; Hiroyuki Honda; Kazumasa Wakamatsu; Katsutoshi Murase; Satoshi Nohara; Eiichi Nakayama; Takeo Hasegawa; Itsuo Yamamoto; Takeshi Kobayashi
Journal:  J Skin Cancer       Date:  2013-02-21

5.  Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo-immunotherapy.

Authors:  Tomoaki Takada; Toshiharu Yamashita; Makito Sato; Akiko Sato; Ichiro Ono; Yasuaki Tamura; Noriyuki Sato; Atsushi Miyamoto; Akira Ito; Hiroyuki Honda; Kazumasa Wakamatsu; Shosuke Ito; Kowichi Jimbow
Journal:  J Biomed Biotechnol       Date:  2009-10-08

Review 6.  Tissue-selective therapy of cancer.

Authors:  M V Blagosklonny
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.